(ZLAB) Zai Lab Limited BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ZLAB) Zai Lab Limited Complete Analysis Pack
Actionable Strategy Starts Here
This Zai Lab Limited BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Zejula ovarian maintenance
Zejula is Zai Lab Limited’s flagship oncology brand in Greater China, and ovarian cancer maintenance stays a large, repeat-use market. The PARP inhibitor class is still expanding, so Zejula remains a Star in the BCG Matrix with strong growth potential. Its role in long-term maintenance after platinum response keeps demand durable and clinically relevant.
Qinlock GIST franchise
Qinlock targets advanced GIST after prior kinase therapy, a rare niche with few direct substitutes, so it fits as a Star in Zai Lab Limited's BCG matrix. In INVICTUS, ripretinib cut median PFS to 6.3 months vs 1.0 month with placebo and delivered an 11.8% objective response rate. As physician use grows, the franchise still has room to expand.
Repotrectinib ROS1 TRK NSCLC
Repotrectinib is a next-generation kinase inhibitor for biomarker-defined solid tumors, and ROS1-positive NSCLC is a small but expanding niche, at about 1%-2% of NSCLC cases. In 2025, that rare-disease profile still supports premium pricing and fast uptake where testing is available. If Zai Lab Limited executes launch well, the asset can scale quickly because unmet need is high and the target pool is clear.
Odronextamab B-cell lymphoma
Odronextamab is a CD20xCD3 bispecific antibody in hematologic cancer, and bispecifics remain one of oncology’s fastest-growing classes. In B-cell lymphoma, this can fit a Stars profile if Zai Lab Limited can drive uptake fast; the global bispecific antibody market is still expanding at roughly 40%+ CAGR through 2030.
Its value is tied to commercial execution, because CD20 is a validated lymphoma target and CD3 brings T-cell killing into play. If approved and scaled well, the program can turn into a high-growth revenue driver in lymphoma.
- CD20xCD3 design supports rapid response
- Bispecifics are growing fast in oncology
- Best case: strong lymphoma launch scale
Efgartigimod autoimmune disease
Efgartigimod is an FcRn-targeting biologic for autoimmune disease, and myasthenia gravis remains underdiagnosed in China, where prevalence is still low versus treated need. In Zai Lab Limited's portfolio, this looks like a Star because the franchise can scale fast in a market with limited biologic penetration and strong clinical demand.
- FcRn inhibition targets pathogenic IgG.
- MG demand in China is still underpenetrated.
- Clear blockbuster-style growth case.
Zai Lab’s star drugs drive 2025-2026 growth
Zai Lab Limited’s Stars are high-growth, high-need launches with clear scale potential in 2025-2026. Zejula stays the core driver in ovarian cancer, Qinlock has proven 6.3-month PFS in GIST, and repotrectinib addresses the 1%-2% ROS1-positive NSCLC niche. Odronextamab and efgartigimod add fast-growing hematology and autoimmune upside.
| Asset | Star case | Key number |
|---|---|---|
| Zejula | Ovarian maintenance | Repeat-use market |
| Qinlock | Advanced GIST | 6.3 mo PFS |
| Repotrectinib | ROS1 NSCLC | 1%-2% |
What is included in the product
Detailed Word Document
Zai Lab’s BCG Matrix maps its pipeline and marketed drugs into invest, hold, or divest priorities amid biotech growth and competition.
Editable Excel File
Quick BCG view of Zai Lab Limited to pinpoint cash cows, stars, and drag points fast.
Reference Sources
Lists the key sources behind Zai Lab Limited’s analysis, making the data easier to verify, trust, and use in decisions.
Cash Cows
Zejula recurrent ovarian base
Zejula is Zai Lab Limited’s most mature revenue stream, with an established physician base and repeat use in ovarian cancer maintenance. Growth is slower than newer assets, but it still acts like a classic cash cow: high familiarity, low selling friction, and steadier replenishment from ongoing patient use. In Zai Lab Limited’s latest reported results, Zejula remained a core product, supporting recurring cash generation rather than breakout growth.
Qinlock mature GIST sales
Qinlock is already commercial in China for late-line GIST, a rare cancer with only about 10 to 15 new cases per million people each year. That small, well-defined pool supports repeatable sales once doctors adopt it, so this looks more like a steady cash base than a heavy-growth launch. In BCG terms, mature niche demand can keep Qinlock generating cash with limited extra selling spend.
Optune neuro-oncology base
Optune in glioblastoma fits a Cash Cow profile because it serves a narrow specialist market and is used through tumor-treatment centers, so sales tend to repeat once a center is onboarded. The franchise sits in a disease with about 15-month median survival under standard care, which keeps the need for ongoing, device-based therapy high but growth limited versus launch-stage assets.
Its revenue base is steadier than trial-driven oncology launches because demand is tied to installed center use, patient eligibility, and refill cycles rather than one-time prescribing spikes. That makes Optune a more predictable contributor to Zai Lab Limited’s portfolio, even if the addressable glioblastoma pool is small.
NUZYRA hospital anti-infective base
NUZYRA is Zai Lab Limited's steady hospital anti-infective base, used in acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. It gives recurring demand because these infections keep coming back in inpatient and discharge care, even when growth is not fast. In 2025, its value is cash flow stability, not breakout scale.
- 2 core hospital indications
- Recurring antibiotic demand
- Cash flow over growth
China commercial platform
Zai Lab Limited's China commercial platform is a cash cow because it already has regulatory, medical, and sales coverage in Mainland China and Hong Kong, so each new launch adds far less cost. In 2025, that shared base supported more than one product launch and helped turn approved drugs into recurring revenue. The result is a mature asset that helps fund the pipeline.
- Lower launch cost per new product
- Existing China and Hong Kong reach
- Recurring cash for R&D funding
Zai Lab’s 2025 Cash Cows: Steady R&D Fuel
In 2025, Zai Lab Limiteds Cash Cows were Zejula, Qinlock, Optune, and NUZYRA: mature products with repeat use, niche demand, and low added selling spend. They are less about fast growth and more about steady, recurring cash for R&D.
| Asset | Cash Cow signal |
|---|---|
| Zejula | Established repeat use |
| Qinlock | Rare cancer niche |
| NUZYRA | Recurring hospital demand |
Get Your Copy
Zai Lab Limited Reference Sources
You’re previewing the exact Zai Lab Limited BCG Matrix report you’ll receive after purchase. The full document is the same final version—no demo content, no placeholders, and no watermarks. Once purchased, it’s ready for immediate download, use, or sharing with your team.
Dogs
Margetuximab HER2 cancers
Margetuximab is a Dog for Zai Lab Limited: in HER2 breast and gastroesophageal cancers, it faces entrenched rivals like trastuzumab, pertuzumab, and HER2 ADCs such as Enhertu, which posted 2025 sales above $4 billion globally. The FDA label is limited to post-prior anti-HER2 therapy use, so the addressable pool is narrow. With Zai Lab 2025 total product revenue far more concentrated in core growth assets, margetuximab adds limited upside.
Tebotelimab oncology program
Tebotelimab is still a development-stage oncology asset, so it has 0 commercial sales and no scale yet. In Zai Lab Limited’s BCG Matrix, that fits a Dog profile today. To avoid low-return status, it needs strong Phase 2/3 data and a clear path to approval.
ZL-2309 CDC7 inhibitor
ZL-2309 is an internal, early-stage oncology asset, so it has no launched market and no revenue base today. In BCG terms, that makes it a Dog: low current cash contribution, while development still consumes R&D spend and management time. With revenue at US$0 for this program, it is capital intensive relative to proven cash generation.
ZL-1201 antibody program
ZL-1201 is still in discovery or early development, so it has no established market share and no disclosed 2025/2026 revenue contribution for Zai Lab Limited. In BCG terms, it stays a Dogs asset until proof of concept and clinical data improve. That makes it a weak portfolio contributor right now.
- Early-stage, no market share
- No 2025/2026 sales disclosed
- Weak BCG contributor today
ZL-2314 EGFR inhibitor
ZL-2314 sits in Dogs: it targets EGFR mutation biology in a crowded NSCLC field where EGFR mutations appear in about 10% to 15% of Western and 40% to 50% of Asian lung cancers. With osimertinib already setting a high efficacy bar, Zai Lab Limited needs clear differentiation on response, safety, or resistance coverage or the program stays low-value.
- High competition
- Weak pricing power
- Differentiation is key
Zai Lab’s Dog Assets Burn Cash, Deliver Little Upside
Dogs at Zai Lab Limited are low-share, low-return assets: margetuximab faces entrenched HER2 rivals, tebotelimab has no sales, and ZL-2309, ZL-1201, and ZL-2314 remain early-stage with no 2025/2026 revenue. These programs consume R&D while adding little cash. In a crowded oncology market, weak differentiation keeps upside limited.
| Asset | Dog signal |
|---|---|
| Margetuximab | Narrow label |
| Tebotelimab | 0 sales |
| ZL-2309 | Early-stage |
| ZL-1201 | No revenue |
| ZL-2314 | High competition |
Question Marks
Adagrasib KRAS G12C
Adagrasib targets KRAS G12C solid tumors and already has U.S. approval in NSCLC and colorectal cancer, which supports fast demand in lung cancer, where KRAS mutations appear in about 13% of cases. For Zai Lab Limited, this looks like a Question Mark in China: the market is growing, but share stays unclear until local approval and launch execution land. The upside is real, but so is the regulatory risk.
Bemarituzumab FGFR2b gastric
Bemarituzumab is aimed at FGFR2b-positive gastric and gastroesophageal cancers, a small but high-need segment with no clear standard targeted option. Zai Lab said the drug is still in late-stage development, so it has commercial upside, but it has not yet shown share or launch traction. That makes it a classic Question Mark: high potential, low proven sales.
CLN-081 EGFR exon 20
CLN-081 targets EGFR exon 20 insertion NSCLC, a small but clinically important group that makes up about 2% to 4% of EGFR-mutant NSCLC cases. In Zai Lab Limited’s BCG view, that puts it in Question Marks: high need, but a narrow pool and still uncertain uptake. If it wins share in this niche, especially in China where NSCLC is the top cancer and was about 1.06 million new cases in 2022, it could grow into a real asset.
Elzovantinib kinase inhibitor
Elzovantinib is a multi-targeted kinase program, so it fits Zai Lab Limited's Question Marks: big scope, low proven share. Zai Lab Limited reported 2024 revenue of about $399 million, but Elzovantinib still has no disclosed commercial sales, so value depends on clinical wins, not current demand.
- Broad oncology targets can widen future use
- Current market share is still unproven
- Success now depends on development and approval
KarXT psychiatry neurology
KarXT targets schizophrenia and other neuropsychiatric disorders with very large treated pools; schizophrenia affects about 24 million people worldwide, and China is one of the biggest addressable markets. For Zai Lab Limited, the asset can move from a question mark to a star only if China development, reimbursement, and prescribing uptake all land well. Until local access is proven, the commercial upside stays promising but untested.
- Large patient pool, strong upside
- China access is the key gate
- Still a question mark until uptake shows
Zai Lab’s Question Marks Could Pay Off in China’s Biggest Drug Markets
Adagrasib, bemarituzumab, CLN-081, elzovantinib, and KarXT are Question Marks for Zai Lab Limited because each targets a clear unmet need, but China share is still unproven. The upside is biggest where patient pools are large, like schizophrenia at 24 million people worldwide and NSCLC at 1.06 million new China cases in 2022.
| Asset | Why Question Mark |
|---|---|
| Adagrasib | Approval pending in China |
| Bemarituzumab | Late-stage, no sales |
| CLN-081 | Niche EGFR group |
| KarXT | Big market, unproven uptake |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.